Mengchao Wu

Mengchao’s practice focuses on initial public offerings and other equity capital markets transactions on the Hong Kong Stock Exchange, pre-IPO investments, public takeovers and listing rules and securities regulations compliance.

Prior to joining Cooley, Mengchao has worked at the Beijing office of another leading international law firm.

Mengchao is a native Mandarin speaker and is fluent in English.

Representative Matters:

IPO

• Represented PATEO, a leading provider of smart cockpit and smart internet solutions, in its Hong Kong IPO, in its 1.07 billion Hong Kong IPO  
• Represented Innogen Pharmaceutical, a science-driven biopharmaceutical company dedicated to the research and development of innovative and affordable medicines for metabolic disease patients, in its HK$683 million Hong Kong IPO
• Represented underwriters on the HK$335 million Hong Kong IPO and global offering of Taimei Technology, a provider of digital solutions for life sciences research and development and marketing 
• Represented YZY Bio in its HK$176 million Hong Kong IPO  
• Represented underwriters on the HK$198 million Fenbi Hong Kong IPO
• Represented underwriters on the US$285 million Huitongda Network Co., Ltd’s Hong Kong IPO
• Represented Asymchem in its $818 million Hong Kong IPO (the largest healthcare Hong Kong IPO in 2021)
• Represented underwriters CR Pharmaceutical Holding in its $1.8 billion Hong Kong IPO (the second largest Hong Kong IPO in 2016)
• Represented underwriters China Energy Engineering Group Co., Ltd. in its US$1.8 billion Hong Kong IPO
• Represented Nongfu Spring in its US$1.08 billion Hong Kong IPO (largest subscribed Hong Kong IPO to date)
• Represented underwriters Huazhu Group in its US$783 million Hong Kong IPO
• Represented underwriters Ganfeng Lithium in its US$424 million Hong Kong IPO
• Represented underwriters Jinshang Bank in its US$420 million Hong Kong IPO
• Represented underwriters Weihai City Commercial Bank in its US$365.3 million Hong Kong IPO
• Represented Yichang HEC ChangJiang Pharmaceutical in its US$173.0 million Hong Kong IPO
• Represented underwriters CMGE Technology Group in its US$149 million Hong Kong IPO

Compliance 

• Asymchem (Stock Code: 6821)
• PetroChina Company Limited (Stock Code: 857)
• CITIC Limited (Stock Code: 267)
• Beijing Jingneng Clean Energy (Stock Code: 579)
• MicroPort Scientific Corporation (Stock Code: 853)

Other capital market related business

• Represented China Feihe Limited in completing its conditional general offer to Original Livestock (HK$3.0 billion)
• Represented SHENGJING Bank in the completion of its wash sale waiver transaction to Evergrande Group (HK$2.3 billion)
• Represented PetroChina in its major transaction to sell its pipeline assets to participate in the restructuring of China's pipeline network (RMB268.7 billion)
• Represented Beijing Jingneng Clean Energy in the completion of its directed issue of domestic shares and H shares (HK$450 million)